Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 3CNS 3Gastrointestinal 2Breast 2Sarcoma 1Gynecologic 1Dermatologic 1

Conditions

Sarcoma 1Melanoma 1

Interventions

pembrolizumab 157Nivolumab 132Ipilimumab 77Cyclophosphamide 46Specimen Handling 44Magnetic Resonance Spectroscopy 39cemiplimab 35Biopsy 31fludarabine 28trametinib 24relatlimab 24binimetinib 23Interleukin-2 21fludarabine phosphate 20dabrafenib 20atezolizumab 20Radiotherapy 20Opdualag 19Radiosurgery 18CTLA-4 Antigen 18encorafenib 17aldesleukin 17Blood Specimen Collection 17avelumab 14Immunoglobulin G 14Disulfides 13lenvatinib 11Bevacizumab 11lifileucel 10Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vaccines × Dermatologic × 1 year × Clear all
NCT05264974 2026-05-27

Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization

University of Florida

Phase 1 Suspended
18 enrolled
DermatologicSarcoma

Melanoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡